Growth Hormone's Effect on the Cardiovascular System

• Status: Terminated
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-matched healthy population.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Collaborators: National Center for Research Resources (NCRR); Pfizer
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Adult between the ages of 18 and 65

• Documented Growth Hormone Deficiency as defined by a peak Growth Hormone during a GHRH-Arginine Stimulation test not exceeding 9.5 ng/ml

Exclusion Criteria:

• Personal history of cardiovascular disease (previous myocardial infarction or known coronary artery disease) or diagnosis of heart disease between study visits.

• Personal history of diabetes mellitus or development of diabetes between study visits.

• Initiation of an anti-cholesterol medication or anti-hypertensive between baseline and follow-up study visit.

• Initiation of regular tobacco use between baseline and follow-up study visit.

• Pregnancy or nursing

• Current daily use of any drug known to affect the fibrinolytic system: Aspirin, Aggrenox, Plavix, Persantine, Ticlid, Pletal, Trental, Lovenox, Coumadin, Agrylin, and Hydroxyurea.